BEVERLY HILLS, California, June 15, 2026 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a biotech company specializing in developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders, is pleased to provide a corporate update, highlighting an overview of developments in its subsidiaries, Oricidin, Bio-Convert and NoviThera, and a status of the Company’s Nasdaq uplisting application.
Orocidin:
Orocidin’s QR-01 targets aggressive periodontitis, a severe form of periodontal disease with no approved medical treatment. After completing two toxicology studies on hamsters spanning over 2 weeks and 8 weeks respectively, Orocidin has recently demonstrated QR-01’s efficacy in treating periodontitis in 2 different animal studies using two different methods. These successful studies allow the company to initiate the first human trials of QR-01.
Beagle study:
This 13-day small efficacy study conducted on beagle dogs with clinically confirmed periodontitis demonstrated consistent improvements across key clinical endpoints, including the Gingival Index (GI), the Plaque Index (PI) and overall periodontal disease. The animals were fasted for a minimum of 8 hours prior to assessment of the efficacy. QR-01 was well tolerated in the dogs, with no adverse side effects reported throughout the treatment period, which is significant.
Wistar Rat study:
Rats with induced periodontitis treated with QR-01 demonstrated improvements in Probing Depth (PD-mm), Gingival Index (GI), Bleeding on Probing (BOP) and Plaque Levels (PL).
More importantly, lower bone loss was demonstrated in treated rats compared to non-treated rats measured by micro-CT scanning. Until now, this has not been demonstrated.
In summary, Orocidin has now demonstrated efficacy in treating periodontitis in two different animals using 2 methods. This gives us great expectations in demonstrating efficacy in the upcoming trials in patients.
The first Phase IIa clinical trials study in patients is now anticipated to start in the first half of 2027 at the University of Copenhagen in Denmark.
Bio-Convert:
Bio-Convert’s QR-02 compound targets Oral Leukoplakia (OLK), which are potentially pre-cancerous lesions in the mouth, with up to a 30% conversion rate to oral cancer. No approved medical treatment exists for OLK, with surgery the only true alternative.
The company’s proprietary oral gel QR-02 has several unique advantages, including antitumor & antiviral effects, reducing the risk of dysplasia and enabling more precise and efficient treatment, compared to any methods used today.
Bio-Convert obtained a toxicity waiver from the Danish Medicine Agency’s (DKMA) for QR-02 and is currently finalizing its GMP (Good Manufacturing Practice) product to be completed by December 2026 in Germany. Bio-Convert anticipates moving into Phase IIa clinical trials in Europe beginning the first half of 2027.
NoviThera:
NoviThera’s QR-04 goal is to develop a novel anti-monoclonal antibody treatment designed to cure psoriasis or prevent its occurrence. Currently, no permanent cure for psoriasis exists, leading to a significant unmet medical need for patients and huge market potential.
NoviThera recently completed a study in mice, and with such study demonstrated biological proof of concept.
Uplisting:
Nordicus applied to uplist its common shares from the OTCQB Market to a large prominent stock exchange and the process is still ongoing.
Other Activities:
The Company continues to scout the Nordic region for additional accelerator clients and possible new high growth acquisitions in the life sciences space.
About Nordicus Partners Corporation:
Nordicus Partners Corporation is a U.S. based biotech company focusing on acquiring and developing drugs from innovative biotech companies in the Nordics, a region known for its brilliant scientists, exceptional life science ecosystem and drug discoveries and developments. Nordicus is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs – starting with oral disorders. Its scientific foundation targets inflammation and immune modulation. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert A/S, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. For more information about Nordicus, please visit: www.nordicuspartners.com, and follow us on LinkedIn and X
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” “confident” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition, prospects of being listed on Nasdaq, studies related to Orocidin, Bio-Convert and NoviThera and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.
Elizabeth Addonizio is an experienced finance professional with twenty-five years of business and leadership experience. She is the founder of Fair Winds Capital LLC, AMN LLC, and GEDI LLC, through which she has spent the past decade investing, along with families and entrepreneurs, in U.S.-based, sector-agnostic, early-stage venture investments that prioritize impact and environmental, social, and good governance (ESG) principles by investing in companies’ Pre-seed to C-round capital raises. She has also served as a fractional CFO for many companies in diverse sectors.
Prior to her venture investing and CFO work, from 2012 to 2016, Ms. Addonizio was a founding managing director and investment professional at Cranemere, an international investment holding company and private equity firm structured to invest with a commitment to sustainability and ESG principles, along with other families, in middle market private companies (~$200mm-$500mm in enterprise value). While at Cranemere she sourced and evaluated dozens of investment opportunities, serving on the firm’s Investment Committee, and overseeing due diligence, financing, and other acquisition-related activities. Prior to joining Cranemere, from 2006 to 2012, Ms. Addonizio worked at Morgan Stanley in the Investment Banking and Corporate M&A and Strategy Divisions, advising on over $25 billion of mergers and acquisitions, leveraged finance, and equity transactions.
In addition to her work in finance, since 2004, Ms. Addonizio has served as an intelligence officer in the U.S. Navy Reserve. Currently, she is the board-selected Commanding Officer of the 30-member Navy Reserve Office of Naval Intelligence (ONI) Kennedy Maritime Analysis Center Unit in St. Louis, MO. Previously, she was Executive Officer of 110+-person Navy Reserve Joint Intelligence Operations Center Europe (JIOCEUR) Analytic Center Molesworth 0366 (located at Joint Reserve Intelligence Support Element Sheridan, Fort Sheridan, IL). Prior to this position, she served as the board-selected Executive Officer of 75-person ONI Navy Reserve Nimitz Unit at Fort Dix, NJ. She was also the Officer in Charge (OIC) of a twenty-eight-person Naval Criminal Investigative Service (NCIS) Unit based in New London, CT. Board-selected to hold this position, she was one of only three to have command of a unit at her rank in the Navy Reserve Intelligence Community, the first woman to ever serve in this NCIS unit, and by extension, the unit’s first female OIC. During her twenty years in the U.S. Navy, she has led numerous teams in support of JIOCEUR, ONI, NCIS, and the Defense Intelligence Agency (DIA). She also served 20 months of active military duty as an analyst on the personal staff of the Commander of U.S. Central Command, General David Petraeus.
Earlier in her career, Ms. Addonizio was elected to serve two terms as the 9th Ward Alderwoman in New Haven, Connecticut, serving as the Vice Chair of the Finance Committee with legislative oversight of the city’s $450 million annual budget. As a Henry Luce Scholar in China, she taught economics at Peking University and worked on China’s accession to the World Trade Organization at the World Bank Resident Mission. She has also worked in the U.S. National Security Council and in the Office of the U.S. Trade Representative. She holds a Ph.D. from Yale University, a M.P.A. from Princeton University, a B.A. from Bucknell University, and was a Fulbright Scholar in El Salvador. Ms. Addonizio is currently a member of the Association for Corporate Growth and the Alliance of Merger and Acquisitions Advisers. She is also a Council on Foreign Relations Life Member, a NationSwell Council Member, a Truman National Security Project Fellow, and a Yale World Fellow.